Viral Antigen Expression in Mammalian Cells via T7 Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing immunogenic viral antigens, such as those for viruses like FMDV and PEDV, face challenges in replicating the original protein configurations due to differences in protein synthesis mechanisms between prokaryotes and higher eukaryotes, making it difficult to achieve high-quality and quantity antigen production for vaccines and diagnostic reagents.
Innovation Solution
A co-transfection expression system using a mammalian cell with a vT7 recombinant vaccinia virus expressing T7 polymerase and an expression plasmid containing the T7 promoter and open reading frame (ORF) of the target antigen, allowing for the production of entire viral antigens with original structure, suitable for vaccine preparation and monoclonal antibody screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If viral antigens are produced by direct cultivation of the virus, then the antigen quality closely matches the original virus configuration, but the production quantity and efficiency are limited by viral cultivation constraints
Solution Approach 1:
The patent creates recombinant vaccinia viruses that carry viral antigen genes, effectively copying the antigen-producing capability without requiring cultivation of the actual pathogenic virus. The vaccinia virus serves as a safe vehicle to express and produce large quantities of viral antigens that match the original virus structure
Solution Approach 2:
The vaccinia virus acts as an intermediary system - it is a non-pathogenic poxvirus that can be safely cultivated in mammalian cells while carrying and expressing the genes of the target virus (such as FMDV or PEDV). This intermediary enables high-volume production without the risks and limitations of directly cultivating the original pathogen
2Productivity
If viral antigens are produced by expressing full-length ORF in cells using traditional methods, then the production quantity increases, but the antigen quality may not match the original virus configuration due to differences in protein synthesis mechanisms
Solution Approach 1:
The patent changes the expression system parameters by using vaccinia virus-mediated expression in mammalian cells, which replicates the eukaryotic protein synthesis environment of the original virus. This ensures proper post-translational modifications, folding, and assembly of viral antigens, maintaining structural authenticity while enabling high-level expression
Solution Approach 2:
The vaccinia virus expression system serves multiple functions simultaneously: it provides high-level gene expression, ensures proper eukaryotic protein processing, enables large-scale production in mammalian cells, and maintains antigen structural integrity. This multi-functional system resolves the contradiction between quantity and quality
3Reliability
If traditional viral cultivation methods are used for antigen production, then high biosafety norms are required for pathogenic viruses, but this increases production complexity and cost
Solution Approach 1:
The patent extracts the antigen-producing genes from the pathogenic virus and transfers them into the non-pathogenic vaccinia virus system. This separation removes the biosafety risks associated with cultivating actual pathogenic viruses while retaining the ability to produce authentic viral antigens for vaccine and diagnostic applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system effectively expresses viral antigens with high quality and quantity, enabling the production of immunogenic proteins equivalent to the target virus, facilitating vaccine development and diagnostic applications.
Implementation Method 1
a mammalian cell co-transfected with an expression plasmid comprising T7 promoter and an open reading frame (ORF) for target antigen, and a vT7 recombinant vaccinia virus expressing T7 polymerase
Implementation Method 2
The mammalian cell/antigen expresses an entire viral antigen with original structure
Data Source
AI summary
A mammalian cell co-transfect with an expression plasmid comprising T7 promoter and an open reading frame (ORF) of target antigen, and a vT7 recombinant vaccinia virus expressing T7 polymerase. The entire antigen expressing cell is used as a carrier of the target antigen for preparing a vaccine or diagnostic agent, and screening monoclonal antibodies.